Pharmaceuticals

AbbVie cuts ties with Google-backed longevity firm Calico, lays off scientists

Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT’s industry-leading events.

AbbVie is ending a decade-long partnership with Calico Life Sciences, an Alphabet-funded biotech company focused on aging research, and laying off chemists working on discovering new drugs.

The moves, detailed in internal emails sent Tuesday and viewed by STAT, come as the pharmaceutical giant is moving away from small-molecule drugs, which include pills, and investing more in injectable therapies and complex genetic medicines. 

AbbVie did not immediately respond to a request for comment Wednesday.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

No Byline Policy

Editorial Guidelines

Corrections Policy

Source

Leave a Reply